From drug discovery to drug design.
Ten63 brings Superlearning to drug discovery: pairing generative chemistry with quantum-accurate simulation to design therapeutics for currently intractable diseases.
And new data is brutally slow.
Every hypothesis has to be physically made and tested. Synthesis and assays are slow and costly, so the data that would unlock the rest barely trickles in.
So we made the simulation indistinguishable from reality.
Generate the data in silico, learn from it instantly, and the frontier moves. Superlearning turns the undruggable into the druggable.
Most of biology is still dark.
Models are only as good as their data, and the best of it is a vanishing slice of chemistry. Roughly 80% of the human proteome stays undruggable.
Step inside the model where chemistry becomes computable.
BEYOND, the world's first Large Quantum Chemistry Model.
Quantum-physics levels of accuracy at the speed of classical molecular mechanics. BEYOND virtually explores more than 100 trillion molecules, guided by a simulation environment that closely tracks experimental reality, to design optimal solutions.
* Internal benchmarks vs Meta UMA-M.
BEYOND is the most accurate simulation.
BEYOND achieves state-of-the-art accuracy at unprecedented speed.
Only BEYOND breaks the trade-off frontier.
Until now, simulation forced a choice: accurate or fast. Highly accurate methods would take millions of years; fast methods have little predictive power. BEYOND clears both the quantum-accuracy and simulation-efficiency barriers at once.
A clear path to drug-discovery superintelligence.
BEYOND creates the perfect environment for Superlearning. Industry-leading generative chemistry explores over 100 trillion molecules per pocket, while quantum-accurate simulations enable in silico experiments that are nearly indistinguishable from reality, at unprecedented scale. Each makes the other smarter, compounding toward superintelligence.
Breakthroughs against previously undruggable and under-drugged targets.
Every program starts with intelligence at scale. Sentinel, our virtual CSO, continuously scans all publicly available information and proposes targets ranked by confidence and weighted by patient need. Sentinel establishes a translational plan and identifies killer experiments before BEYOND ever designs a molecule.
The result: an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases, advancing toward a future where no loved one is lost to disease.
An interdisciplinary team driving our mission.
Founders and operators from Duke, Pfizer, Genentech, and Mirati, uniting chemistry, physics, biology, and AI.
Our investors.
Strategic and venture investors committed to building a better future for patients.
